Diabetic Medications and Insulin Pump Therapies- 6HR

Course overview

Audience: This medication-rich course is for all pharmacists responsible for managing patients with diabetes. Course Overview: Diabetes and glycemic medications are in the news every day. Staying ahead of current research and treatment options is an uphill challenge. This course provides the latest in diabetic medications and treatment options, including insulin pump therapies. Objectives: Upon completion of this education program, the learner should be able to: 1. Describe the normal processing of blood glucose in a healthy person. 2. Discuss the altered processing of blood glucose in diabetic patients. 3. Recognize the effects of sulfonylureas on blood glucose control, cardiovascular effects of sulfonylureas, their adverse reactions, and the currently available sulfonylureas. 4. Describe the characteristics of meglitinides, including effects on blood glucose control, cardiovascular effects, adverse reactions, and the medications available in this class. 5. Discuss metformin’s effects on blood glucose control, cardiovascular effects, and its potential adverse reactions. 6. Recognize the characteristics of thiazolidinediones, including effects on blood glucose control, impact on cardiovascular health, and contraindications to the use of this class of medication. 7. Explain the effects of amylin analogs on blood glucose control, cardiovascular effects, adverse reactions, and their dosing. 8. Describe the characteristics of alpha glucosidase inhibitors, including effects on blood glucose control, cardiovascular effects, and the dosing and availability of these agents. 9. Discuss the characteristics of glucagon-like peptide-1 (GLP-1) receptor agonists, including effects on blood glucose control, cardiovascular effects, adverse reactions, and the use of short-acting vs. long-acting agents. 10. Explain the characteristics of dipeptidyl peptidase-4 (DPP-4) inhibitors, including effects on blood glucose control, cardiovascular effects, adverse reactions, and the currently available DPP-4 inhibitors.